135 related articles for article (PubMed ID: 9268722)
1. Chimeric D2/D3 dopamine receptor coupling to adenylyl cyclase.
Lachowicz JE; Sibley DR
Biochem Biophys Res Commun; 1997 Aug; 237(2):394-9. PubMed ID: 9268722
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
Van Leeuwen DH; Eisenstein J; O'Malley K; MacKenzie RG
Mol Pharmacol; 1995 Aug; 48(2):344-51. PubMed ID: 7651368
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of a chimeric hD3/D2 dopamine receptor expressed in CHO cells.
McAllister G; Knowles MR; Patel S; Marwood R; Emms F; Seabrook GR; Graziano M; Borkowski D; Hey PJ; Freedman SB
FEBS Lett; 1993 Jun; 324(1):81-6. PubMed ID: 8099332
[TBL] [Abstract][Full Text] [Related]
4. Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells.
Robinson SW; Caron MG
J Neurochem; 1996 Jul; 67(1):212-9. PubMed ID: 8666994
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells.
Vanhauwe JF; Fraeyman N; Francken BJ; Luyten WH; Leysen JE
J Pharmacol Exp Ther; 1999 Aug; 290(2):908-16. PubMed ID: 10411608
[TBL] [Abstract][Full Text] [Related]
6. Chimeric D1/D2 dopamine receptors. Distinct determinants of selective efficacy, potency, and signal transduction.
Kozell LB; Machida CA; Neve RL; Neve KA
J Biol Chem; 1994 Dec; 269(48):30299-306. PubMed ID: 7982941
[TBL] [Abstract][Full Text] [Related]
7. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.
Chio CL; Lajiness ME; Huff RM
Mol Pharmacol; 1994 Jan; 45(1):51-60. PubMed ID: 8302280
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor.
Robinson SW; Caron MG
Mol Pharmacol; 1997 Sep; 52(3):508-14. PubMed ID: 9281614
[TBL] [Abstract][Full Text] [Related]
9. Coupling of dopamine receptors to G proteins: studies with chimeric D2/D3 dopamine receptors.
Ilani T; Fishburn CS; Levavi-Sivan B; Carmon S; Raveh L; Fuchs S
Cell Mol Neurobiol; 2002 Feb; 22(1):47-56. PubMed ID: 12064517
[TBL] [Abstract][Full Text] [Related]
10. Effects of reciprocal chimeras between the C-terminal portion of third intracellular loops of the human dopamine D2 and D3 receptors.
Filteau F; Veilleux F; Lévesque D
FEBS Lett; 1999 Mar; 447(2-3):251-6. PubMed ID: 10214956
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.
Watts VJ; Neve KA
Mol Pharmacol; 1996 Oct; 50(4):966-76. PubMed ID: 8863843
[TBL] [Abstract][Full Text] [Related]
12. Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs.
Obadiah J; Avidor-Reiss T; Fishburn CS; Carmon S; Bayewitch M; Vogel Z; Fuchs S; Levavi-Sivan B
Cell Mol Neurobiol; 1999 Oct; 19(5):653-64. PubMed ID: 10384262
[TBL] [Abstract][Full Text] [Related]
13. 7-OH-DPAT antagonizes dopamine D2 receptor-inhibited adenylyl cyclase activity.
Izenwasser S; Katz JL
Life Sci; 1994; 55(14):PL257-9. PubMed ID: 8090051
[TBL] [Abstract][Full Text] [Related]
14. SH3 binding domains in the dopamine D4 receptor.
Oldenhof J; Vickery R; Anafi M; Oak J; Ray A; Schoots O; Pawson T; von Zastrow M; Van Tol HH
Biochemistry; 1998 Nov; 37(45):15726-36. PubMed ID: 9843378
[TBL] [Abstract][Full Text] [Related]
15. Dysbindin-1 modifies signaling and cellular localization of recombinant, human D₃ and D₂ receptors.
Schmieg N; Rocchi C; Romeo S; Maggio R; Millan MJ; Mannoury la Cour C
J Neurochem; 2016 Mar; 136(5):1037-51. PubMed ID: 26685100
[TBL] [Abstract][Full Text] [Related]
16. High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains.
Robinson SW; Jarvie KR; Caron MG
Mol Pharmacol; 1994 Aug; 46(2):352-6. PubMed ID: 7915820
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3'5'-cyclic monophosphate (cAMP) accumulation via D2L (long isoform) and D3 receptors expressed in Chinese hamster ovary (CHO) cells.
Hall DA; Strange PG
Biochem Pharmacol; 1999 Jul; 58(2):285-9. PubMed ID: 10423170
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
MacKenzie RG; VanLeeuwen D; Pugsley TA; Shih YH; Demattos S; Tang L; Todd RD; O'Malley KL
Eur J Pharmacol; 1994 Jan; 266(1):79-85. PubMed ID: 7907989
[TBL] [Abstract][Full Text] [Related]
19. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
Maggio R; Scarselli M; Novi F; Millan MJ; Corsini GU
J Neurochem; 2003 Nov; 87(3):631-41. PubMed ID: 14535946
[TBL] [Abstract][Full Text] [Related]
20. Comparison of agonist potencies at human dopamine D2 and D3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer.
Boyfield I; Winn F; Coldwell M
Biochem Soc Trans; 1996 Feb; 24(1):57S. PubMed ID: 8674731
[No Abstract] [Full Text] [Related]
[Next] [New Search]
